Analysis of FOXC2 mRNA levels in a large cohort of breast cancer patient samples (METABRIC12) revealed significantly elevated levels in the aggressive Basal/Claudin-low subtypes compared to the luminal and HER2 subtypes (Fig 2E). This evidence concerns the gene FOXC2 and breast carcinoma.